XTANDI is a prescription medicine used to treat men with prostate cancer that:
- no longer responds to a hormone therapy or surgical treatment to lower testosterone
- has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone
OR
It is not known if XTANDI is safe and effective in females or children.
Pay as little as
$0 per month.
It's all about
having a game
plan
XTANDI can slow advanced prostate cancer progression.
XTANDI is a prescription medicine used to treat men with prostate cancer that no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone. It is not known if XTANDI is safe and effective in females or children.
XTANDI is FDA-approved to treat 3 forms of advanced prostate cancer.
Metastatic castration-sensitive prostate cancer (mCSPC)
In a study with 1,150 men where the cancer had spread to other parts of the body and still responded to treatment to lower testosterone, XTANDI lowered the chance of progression by 61%.
The median* length of time until the cancer got worse was not reached for XTANDI + ADT** vs. 19 months for ADT alone.
Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason.
The trial is ongoing to determine effect on overall survival.
Metastatic castration-resistant prostate cancer (mCRPC)
In a study with 1,717 men where the cancer had spread to other parts of the body and no longer responded to treatment to lower testosterone, XTANDI lowered the chance of progression by 83%.
The median length of time until the cancer got worse was not reached for XTANDI + ADT vs. 4 months for ADT alone.
Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason.
Non-metastatic castration-resistant prostate cancer (nmCRPC)
In a study with 1,401 men where the cancer had not spread to other parts of the body and no longer responded to treatment to lower testosterone, XTANDI lowered the chance of progression by 71%.
The median length of time until the cancer spread was 37 months for XTANDI + ADT vs. 15 months for ADT alone.
Progression was defined as the cancer spreading, as measured by scans, or if the patient died for any reason.
Results may vary. Talk with your doctor about what this may mean for you.
*The median is not the average but the middle of a set of numbers.
**ADT=Androgen Deprivation Therapy.
Select Safety Information
XTANDI may cause serious side effects, including seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure.
Stay informed
Whether you’re a patient or caregiver, you’re not fighting alone. We’re here for you with tools, tips, information, and support.
Pat, his wife and caregiver.
Copay Assistance for Commercially Insured Patients
The XTANDI Patient Savings Program* is for eligible patients who have commercial prescription insurance.
Copay Assistance for Commercially Insured Patients
The XTANDI Patient Savings Program* is for eligible patients who have commercial prescription insurance.
